OR WAIT 15 SECS
The UCL-Pall Biotech Centre of Excellence will address industry challenges and provide workforce training.
Pall Corporation and the University College London (UCL) Biochemical Engineering department created the UCL-Pall Biotech Centre of Excellence (CoE) for research and training, which will be operational from September 2018 through 2024.
A management committee will be supported by UCL’s Strategic Alliance Director, Naveraj Gill. The investment in the UCL Biochemical Engineering’s industrial research collaboration program with Pall Biotech is valued at EUR 2.7 million ($3.5 million) and is staffed by nine engineering doctorates (EngDs) and a fully funded post-doctoral research associate. The organizations will engage in multi-level interactions to enable knowledge transfer and address crucial industry challenges.
“For many years we have collaborated with the Pall Biotech team to overcome industry challenges at the supply level. The new CoE will work to enhance drug production and empower the future workforce,” said Gill in the press release. “UCL colleagues Daniel Bracewell, professor of Bioprocess Analysis, and Mike Hoare, professor of Biochemical Engineering, will bring this vision to life internally. Rick Morris, senior vice-president, Pall Biotech R&D, Richard Gutman, Distinguished Fellow and John Welsh, senior manager Pall Biotech Process R&D, will align with us externally.”
The UCL Biochemical Engineering department takes a unique multidisciplinary approach focused on translational research with strategic partners, such as major pharmaceutical manufacturers or suppliers like Pall Biotech, to gain real-life insight into industry challenges.
Source: Pall Biotech